Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
15.18
-0.15 (-0.98%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Takeda Pharmaceutical Revenue
Takeda Pharmaceutical had revenue of 1.14T JPY in the quarter ending December 31, 2024, with 2.96% growth. This brings the company's revenue in the last twelve months to 4.58T, up 9.83% year-over-year. In the fiscal year ending March 31, 2024, Takeda Pharmaceutical had annual revenue of 4.26T with 5.87% growth.
Revenue (ttm)
4,579.02B JPY
Revenue Growth
+9.83%
P/S Ratio
1.59
Revenue / Employee
92,916,560 JPY
Employees
49,281
Market Cap
46.38B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
| Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
| Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
| Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
| Mar 31, 2020 | 3,291.19B | 1,193.96B | 56.93% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
TAK News
- 15 days ago - BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3 - Accesswire
- 22 days ago - Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns - Seeking Alpha
- 5 weeks ago - Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds - Seeking Alpha
- 7 weeks ago - Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera - Business Wire
- 2 months ago - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) - PRNewsWire
- 2 months ago - Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued - Seeking Alpha
- 2 months ago - Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Suffolk Celebrates Topping off for a Game-Changing New Takeda Facility in Kendall Square Where Science, Art and Community Will Converge - Business Wire